FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3126553617> ?p ?o ?g. }

• W3126553617 endingPage "1749" @default.
• W3126553617 startingPage "1735" @default.
• W3126553617 abstract "Background: People with type 2 diabetes and chronic kidney disease experience a high burden of hypertension, but the magnitude and consistency of blood pressure (BP) lowering with canagliflozin in this population are uncertain. Whether the effects of canagliflozin on kidney and cardiovascular outcomes vary by baseline BP or BP-lowering therapy is also unknown. Methods: The CREDENCE trial (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) randomized people with type 2 diabetes and chronic kidney disease to canagliflozin or placebo. In a post hoc analysis, we investigated the effect of canagliflozin on systolic BP across subgroups defined by baseline systolic BP, number of BP-lowering drug classes, and history of apparent treatment-resistant hypertension (BP ≥130/80 mm Hg while receiving ≥3 classes of BP-lowering drugs, including a diuretic). We also assessed whether effects on clinical outcomes differed across these subgroups. Results: The trial included 4401 participants, of whom 3361 (76.4%) had baseline systolic BP ≥130 mm Hg, and 1371 (31.2%) had resistant hypertension. By week 3, canagliflozin reduced systolic BP by 3.50 mm Hg (95% CI, –4.27 to –2.72), an effect maintained over the duration of the trial, with similar reductions across BP and BP-lowering therapy subgroups (all P interaction ≥0.05). Canagliflozin also reduced the need for initiation of additional BP-lowering agents during the trial (hazard ratio, 0.68 [95% CI, 0.61–0.75]). The effect of canagliflozin on kidney failure, doubling of serum creatinine, or death caused by kidney or cardiovascular disease (hazard ratio, 0.70 [95% CI, 0.59–0.82]) was consistent across BP and BP-lowering therapy subgroups (all P interaction ≥0.35), as were effects on other key kidney, cardiovascular, and safety outcomes. Conclusions: In people with type 2 diabetes and chronic kidney disease, canagliflozin lowers systolic BP across all BP-defined subgroups and reduces the need for additional BP-lowering agents. These findings support use of canagliflozin for end-organ protection and as an adjunct BP-lowering therapy in people with chronic kidney disease. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02065791." @default.
• W3126553617 created "2021-02-15" @default.
• W3126553617 creator A5012514694 @default.
• W3126553617 creator A5015488634 @default.
• W3126553617 creator A5016584401 @default.
• W3126553617 creator A5017476596 @default.
• W3126553617 creator A5018138746 @default.
• W3126553617 creator A5026602252 @default.
• W3126553617 creator A5027520502 @default.
• W3126553617 creator A5031624913 @default.
• W3126553617 creator A5033623434 @default.
• W3126553617 creator A5039432822 @default.
• W3126553617 creator A5040550338 @default.
• W3126553617 creator A5045497276 @default.
• W3126553617 creator A5046130400 @default.
• W3126553617 creator A5046692355 @default.
• W3126553617 creator A5048876790 @default.
• W3126553617 creator A5051708137 @default.
• W3126553617 creator A5053357823 @default.
• W3126553617 creator A5056130529 @default.
• W3126553617 creator A5057261158 @default.
• W3126553617 creator A5069865054 @default.
• W3126553617 creator A5070120817 @default.
• W3126553617 creator A5075162144 @default.
• W3126553617 creator A5088394454 @default.
• W3126553617 date "2021-05-04" @default.
• W3126553617 modified "2023-10-16" @default.
• W3126553617 title "Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease" @default.
• W3126553617 cites W1844817513 @default.
• W3126553617 cites W1948592297 @default.
• W3126553617 cites W2038981426 @default.
• W3126553617 cites W2134304394 @default.
• W3126553617 cites W2138173919 @default.
• W3126553617 cites W2146264128 @default.
• W3126553617 cites W2148513135 @default.
• W3126553617 cites W2154525074 @default.
• W3126553617 cites W2160547085 @default.
• W3126553617 cites W2194668499 @default.
• W3126553617 cites W2214725575 @default.
• W3126553617 cites W2492672367 @default.
• W3126553617 cites W2530979034 @default.
• W3126553617 cites W2618856448 @default.
• W3126553617 cites W2626446274 @default.
• W3126553617 cites W2748201042 @default.
• W3126553617 cites W2750589886 @default.
• W3126553617 cites W2768267412 @default.
• W3126553617 cites W2772844083 @default.
• W3126553617 cites W2794310633 @default.
• W3126553617 cites W2808725516 @default.
• W3126553617 cites W2883804454 @default.
• W3126553617 cites W2900413769 @default.
• W3126553617 cites W2903192033 @default.
• W3126553617 cites W2913564090 @default.
• W3126553617 cites W2920258695 @default.
• W3126553617 cites W2923754537 @default.
• W3126553617 cites W2939222610 @default.
• W3126553617 cites W2952211646 @default.
• W3126553617 cites W2971414122 @default.
• W3126553617 cites W3003318708 @default.
• W3126553617 cites W3004108046 @default.
• W3126553617 cites W3011186745 @default.
• W3126553617 cites W3022616650 @default.
• W3126553617 cites W3028085141 @default.
• W3126553617 cites W3088173406 @default.
• W3126553617 cites W3089612515 @default.
• W3126553617 cites W3129954143 @default.
• W3126553617 cites W4254135372 @default.
• W3126553617 doi "https://doi.org/10.1161/circulationaha.120.048740" @default.
• W3126553617 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33554616" @default.
• W3126553617 hasPublicationYear "2021" @default.
• W3126553617 type Work @default.
• W3126553617 sameAs 3126553617 @default.
• W3126553617 citedByCount "49" @default.
• W3126553617 countsByYear W31265536172021 @default.
• W3126553617 countsByYear W31265536172022 @default.
• W3126553617 countsByYear W31265536172023 @default.
• W3126553617 crossrefType "journal-article" @default.
• W3126553617 hasAuthorship W3126553617A5012514694 @default.
• W3126553617 hasAuthorship W3126553617A5015488634 @default.
• W3126553617 hasAuthorship W3126553617A5016584401 @default.
• W3126553617 hasAuthorship W3126553617A5017476596 @default.
• W3126553617 hasAuthorship W3126553617A5018138746 @default.
• W3126553617 hasAuthorship W3126553617A5026602252 @default.
• W3126553617 hasAuthorship W3126553617A5027520502 @default.
• W3126553617 hasAuthorship W3126553617A5031624913 @default.
• W3126553617 hasAuthorship W3126553617A5033623434 @default.
• W3126553617 hasAuthorship W3126553617A5039432822 @default.
• W3126553617 hasAuthorship W3126553617A5040550338 @default.
• W3126553617 hasAuthorship W3126553617A5045497276 @default.
• W3126553617 hasAuthorship W3126553617A5046130400 @default.
• W3126553617 hasAuthorship W3126553617A5046692355 @default.
• W3126553617 hasAuthorship W3126553617A5048876790 @default.
• W3126553617 hasAuthorship W3126553617A5051708137 @default.
• W3126553617 hasAuthorship W3126553617A5053357823 @default.
• W3126553617 hasAuthorship W3126553617A5056130529 @default.
• W3126553617 hasAuthorship W3126553617A5057261158 @default.
• W3126553617 hasAuthorship W3126553617A5069865054 @default.
• W3126553617 hasAuthorship W3126553617A5070120817 @default.

• next